DE2510620C2 - Festes, zum Einnehmen bestimmtes, im Magensaft schwimmfähiges Arzneimittel - Google Patents
Festes, zum Einnehmen bestimmtes, im Magensaft schwimmfähiges ArzneimittelInfo
- Publication number
- DE2510620C2 DE2510620C2 DE2510620A DE2510620A DE2510620C2 DE 2510620 C2 DE2510620 C2 DE 2510620C2 DE 2510620 A DE2510620 A DE 2510620A DE 2510620 A DE2510620 A DE 2510620A DE 2510620 C2 DE2510620 C2 DE 2510620C2
- Authority
- DE
- Germany
- Prior art keywords
- active ingredient
- medicament according
- sugar
- gastric juice
- crust
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title claims description 25
- 210000004051 gastric juice Anatomy 0.000 title claims description 17
- 239000007787 solid Substances 0.000 title claims description 8
- 239000011248 coating agent Substances 0.000 claims description 23
- 238000000576 coating method Methods 0.000 claims description 22
- 239000001856 Ethyl cellulose Substances 0.000 claims description 16
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 16
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 16
- 229920001249 ethyl cellulose Polymers 0.000 claims description 16
- 210000002784 stomach Anatomy 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 8
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 239000007902 hard capsule Substances 0.000 claims description 7
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 6
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 229920006327 polystyrene foam Polymers 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- -1 ethyl hydroxypropyl Chemical group 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000011872 intimate mixture Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 9
- 229960005439 propantheline bromide Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000209094 Oryza Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- ZEEXVYNJSAWEML-UHFFFAOYSA-N 3-[4-(4-methylphenyl)sulfanyl-3-nitrophenyl]prop-2-enoic acid Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C=CC(O)=O)C=C1[N+]([O-])=O ZEEXVYNJSAWEML-UHFFFAOYSA-N 0.000 description 4
- 229960001377 benactyzine hydrochloride Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 2
- 229960000943 tartrazine Drugs 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2767374A JPS5512411B2 (cg-RX-API-DMAC10.html) | 1974-03-12 | 1974-03-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2510620A1 DE2510620A1 (de) | 1975-09-18 |
| DE2510620C2 true DE2510620C2 (de) | 1984-01-05 |
Family
ID=12227459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2510620A Expired DE2510620C2 (de) | 1974-03-12 | 1975-03-11 | Festes, zum Einnehmen bestimmtes, im Magensaft schwimmfähiges Arzneimittel |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3976764A (cg-RX-API-DMAC10.html) |
| JP (1) | JPS5512411B2 (cg-RX-API-DMAC10.html) |
| BE (1) | BE826498A (cg-RX-API-DMAC10.html) |
| CA (1) | CA1054056A (cg-RX-API-DMAC10.html) |
| CH (1) | CH604719A5 (cg-RX-API-DMAC10.html) |
| DE (1) | DE2510620C2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK142802B (cg-RX-API-DMAC10.html) |
| ES (1) | ES435500A1 (cg-RX-API-DMAC10.html) |
| FR (1) | FR2263744B1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB1507521A (cg-RX-API-DMAC10.html) |
| NL (1) | NL7502952A (cg-RX-API-DMAC10.html) |
| SE (1) | SE409286B (cg-RX-API-DMAC10.html) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH630257A5 (en) * | 1975-03-17 | 1982-06-15 | Hoffmann La Roche | Sustained release formulation |
| US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4207890A (en) * | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
| JPS6024767B2 (ja) * | 1979-08-24 | 1985-06-14 | 塩野義製薬株式会社 | 腸溶性硬カプセル剤 |
| WO1983000284A1 (en) * | 1981-07-15 | 1983-02-03 | Key Pharma | Sustained release theophylline |
| US4451260A (en) * | 1982-03-26 | 1984-05-29 | Minnesota Mining And Manufacturing Company | Sustained release oral medicinal delivery device |
| JPS5953410A (ja) * | 1982-09-20 | 1984-03-28 | Fujisawa Pharmaceut Co Ltd | 新型ソフトカプセル剤 |
| JPS59193831A (ja) * | 1983-04-18 | 1984-11-02 | Sankyo Co Ltd | 腸溶性製剤の製造法 |
| US4505890A (en) * | 1983-06-30 | 1985-03-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation and method |
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| US4610870A (en) * | 1984-10-05 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| JPS61107782U (cg-RX-API-DMAC10.html) * | 1984-12-19 | 1986-07-08 | ||
| US4735804A (en) * | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4767627A (en) * | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4758436A (en) * | 1985-05-29 | 1988-07-19 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4814178A (en) * | 1987-07-01 | 1989-03-21 | Sanford Bolton | Floating sustained release therapeutic compositions |
| DE3803482A1 (de) * | 1988-02-05 | 1989-08-17 | Lohmann Therapie Syst Lts | Schwimmfaehiges orales therapeutisches system |
| JPH082781B2 (ja) * | 1988-10-18 | 1996-01-17 | 嘉明 川島 | 中空顆粒状医薬及びその製法 |
| WO1992000066A1 (en) * | 1990-06-25 | 1992-01-09 | The Du Pont Merck Pharmaceutical Company | Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules |
| US5232704A (en) * | 1990-12-19 | 1993-08-03 | G. D. Searle & Co. | Sustained release, bilayer buoyant dosage form |
| US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
| US5314696A (en) * | 1991-06-27 | 1994-05-24 | Paulos Manley A | Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor |
| DE4406424A1 (de) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| JP2671257B2 (ja) * | 1995-07-13 | 1997-10-29 | エーザイ株式会社 | 溶解遅延性ゼラチン製剤組成物 |
| SE9702533D0 (sv) | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
| IN186245B (cg-RX-API-DMAC10.html) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| EP1063973B1 (en) | 1998-03-19 | 2016-11-16 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| EP1245227A1 (en) * | 2001-03-31 | 2002-10-02 | Jagotec Ag | A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same |
| US20030203027A1 (en) * | 2002-04-26 | 2003-10-30 | Ethicon, Inc. | Coating technique for deposition of drug substance on a substrate |
| US20040086566A1 (en) * | 2002-11-04 | 2004-05-06 | Alpharma, Inc. | Waxy matrix dosage forms |
| US7485322B2 (en) * | 2002-12-24 | 2009-02-03 | Lek Pharmaceuticals D.D. | Modified release pharmaceutical composition |
| WO2004073695A1 (en) * | 2003-02-21 | 2004-09-02 | Lek Pharmaceuticals D.D | Therapeutic system comprising amoxicillin and clavulanic acid |
| EP1680098A4 (en) * | 2003-11-04 | 2012-06-13 | Supernus Pharmaceuticals Inc | DELAYED RELEASE OF POSITIVELY-LOADED PHARMACOLOGICALLY EFFECTIVE MOLECULES FROM A POLYMER-CONTAINING MATRIX WITH POLARIZED OXYGENATOMES |
| AU2007323018B2 (en) * | 2006-09-04 | 2011-02-03 | Panacea Biotec Limited | Programmable buoyant delivery technology |
| WO2009087665A2 (en) * | 2007-12-11 | 2009-07-16 | Vishwanath Sudhir Nande | Novel gastroretentive drug delivery system |
| GB2462022B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| KR20110042366A (ko) * | 2008-08-18 | 2011-04-26 | 팀 아카데미 오브 파마슈티컬 사이언스 | 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용 |
| FR2945945B1 (fr) * | 2009-05-29 | 2011-07-29 | Flamel Tech Sa | Procede de preparation de particules creuses et leurs applications |
| FR2945947B1 (fr) | 2009-05-29 | 2011-07-29 | Flamel Tech Sa | Compositions pharmaceutiques flottantes a liberation controlee |
| JP5594484B2 (ja) * | 2009-07-06 | 2014-09-24 | 杏林製薬株式会社 | 中空構造を有する錠剤 |
| US9314430B2 (en) * | 2010-07-05 | 2016-04-19 | Jagotec Ag | Floating gastric retentive dosage form |
| BR112014000773A8 (pt) * | 2011-07-14 | 2017-10-03 | Apet Holding B V | Composições de nicotinamida e uso terapêutico das mesmas |
| WO2014014348A1 (en) * | 2012-07-16 | 2014-01-23 | APET Holding B.V. | Gastro-retentive drug delivery system |
| WO2013054285A1 (en) | 2011-10-11 | 2013-04-18 | Ranbaxy Laboratories Limited | A gastroretentive dosage system and process of preparation thereof |
| ES2536836T3 (es) | 2012-10-12 | 2015-05-29 | Omya International Ag | Formulación de medicamento gastrorretentivo y sistemas de liberación y su método de preparación usando carbonato de calcio transformado en funcional |
| CA2951909C (en) | 2014-06-11 | 2022-08-16 | Massachusetts Institute Of Technology | Self-assembled residence devices and related methods |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| EP3034070A1 (en) | 2014-12-18 | 2016-06-22 | Omya International AG | Method for the production of a pharmaceutical delivery system |
| EP3069713A1 (en) | 2015-03-20 | 2016-09-21 | Omya International AG | Dispersible dosage form |
| CN104706613B (zh) * | 2015-03-20 | 2018-01-16 | 华侨大学 | 一种胃漂浮空心缓释片的制备方法 |
| JP2018515476A (ja) | 2015-05-01 | 2018-06-14 | マサチューセッツ インスティテュート オブ テクノロジー | 誘発性形状記憶誘導デバイス |
| HK1258050A1 (zh) | 2015-10-23 | 2019-11-01 | Lyndra Therapeutics, Inc. | 用於治疗剂缓释的胃驻留系统及其使用方法 |
| EP3386488B1 (en) | 2015-12-08 | 2023-09-06 | Lyndra Therapeutics, Inc. | Geometric configurations for gastric residence systems |
| JP2019512468A (ja) * | 2016-03-18 | 2019-05-16 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 浮遊性の薬学的剤形 |
| CN119925721A (zh) | 2016-05-27 | 2025-05-06 | 林德拉治疗公司 | 用于胃驻留系统的材料结构 |
| EP3269361A1 (en) | 2016-07-14 | 2018-01-17 | Omya International AG | Dosage form |
| CN118766834A (zh) | 2016-09-30 | 2024-10-15 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
| AU2018279853B2 (en) | 2017-06-09 | 2024-07-04 | Nortiva Bio, Inc. | Gastric residence systems with release rate-modulating films |
| US20230009115A1 (en) * | 2020-03-02 | 2023-01-12 | Craft Health Pte Ltd | Oral dosage forms for extended drug release |
| EP4008509B1 (de) * | 2020-10-14 | 2023-06-07 | Bichsel, Hannes | Geschäumte biogranulatkörner |
| WO2023166225A1 (en) * | 2022-03-04 | 2023-09-07 | APET Holding B.V. | Digestive enzyme formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3418999A (en) * | 1964-02-12 | 1968-12-31 | Donald W. Davis | Method of swallowing a pill |
| FR1454013A (fr) * | 1965-08-18 | 1966-07-22 | Pluripharm | Mode de présentation de deux médicaments associés |
| US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
-
1974
- 1974-03-12 JP JP2767374A patent/JPS5512411B2/ja not_active Expired
-
1975
- 1975-03-10 FR FR7507336A patent/FR2263744B1/fr not_active Expired
- 1975-03-10 BE BE154189A patent/BE826498A/xx not_active IP Right Cessation
- 1975-03-11 DE DE2510620A patent/DE2510620C2/de not_active Expired
- 1975-03-11 SE SE7502725A patent/SE409286B/xx not_active IP Right Cessation
- 1975-03-11 ES ES435500A patent/ES435500A1/es not_active Expired
- 1975-03-11 US US05/557,408 patent/US3976764A/en not_active Expired - Lifetime
- 1975-03-11 DK DK97875AA patent/DK142802B/da not_active IP Right Cessation
- 1975-03-12 NL NL7502952A patent/NL7502952A/xx not_active Application Discontinuation
- 1975-03-12 GB GB10214/75A patent/GB1507521A/en not_active Expired
- 1975-03-12 CH CH315475A patent/CH604719A5/xx not_active IP Right Cessation
- 1975-03-12 CA CA221,903A patent/CA1054056A/en not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| DK142802C (cg-RX-API-DMAC10.html) | 1981-09-21 |
| FR2263744A1 (cg-RX-API-DMAC10.html) | 1975-10-10 |
| DK97875A (cg-RX-API-DMAC10.html) | 1975-09-13 |
| JPS50121418A (cg-RX-API-DMAC10.html) | 1975-09-23 |
| CH604719A5 (cg-RX-API-DMAC10.html) | 1978-09-15 |
| GB1507521A (en) | 1978-04-19 |
| DK142802B (da) | 1981-02-02 |
| CA1054056A (en) | 1979-05-08 |
| DE2510620A1 (de) | 1975-09-18 |
| US3976764A (en) | 1976-08-24 |
| FR2263744B1 (cg-RX-API-DMAC10.html) | 1978-11-24 |
| SE7502725L (cg-RX-API-DMAC10.html) | 1975-09-15 |
| SE409286B (sv) | 1979-08-13 |
| BE826498A (fr) | 1975-06-30 |
| ES435500A1 (es) | 1977-02-01 |
| NL7502952A (nl) | 1975-09-16 |
| JPS5512411B2 (cg-RX-API-DMAC10.html) | 1980-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2510620C2 (de) | Festes, zum Einnehmen bestimmtes, im Magensaft schwimmfähiges Arzneimittel | |
| US4851226A (en) | Chewable medicament tablet containing means for taste masking | |
| DE69107686T2 (de) | Im Dickdarm zersetzbare Hartkapseln. | |
| DE3853566T2 (de) | Formulierungen von Tetrazyklinverbindungen mit kontrollierter Freisetzung. | |
| DE69934505T2 (de) | Im munde zerfallende tablette enthaltend ein benzimidazole | |
| DE69727922T2 (de) | Schnell zerfallende orale dosierungsform | |
| US3131123A (en) | Enteric tablets and manufacture thereof | |
| DE69022876T3 (de) | Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. | |
| AT396329B (de) | Pharmazeutische granulate und verfahren zu ihrer herstellung | |
| DE69530759T2 (de) | Filmbeschichtete tablette, die paracetamol und domperidone enthält | |
| DD266734A5 (de) | Verfahren zur herstellung von kaernern mit gesteuerter wirkstoffabgabe | |
| CH690955A5 (de) | Oxybutynin umfassende Arzneiform. | |
| CA1336069C (en) | Chewable medicament tablet containing means for taste masking | |
| US5397574A (en) | Controlled release potassium dosage form | |
| CH653550A5 (de) | Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich. | |
| PL176211B1 (pl) | Środek farmaceutyczny w postaci powlekanego granulatu lub powlekanej tabletki do kontrolowanego uwalniania substancji czynnej i sposób wytwarzania środka farmaceutycznego w postaci powlekanego granulatu lub powlekanej tabletki do kontrolowanego uwalniania substancji czynnej | |
| CH670566A5 (cg-RX-API-DMAC10.html) | ||
| DE69815856T2 (de) | Cefadroxilmonohydrat tablettenformulierung | |
| DE2950463A1 (de) | Gallensaeuren enthaltende pharmazeutische zubereitung mit verlaengerter wirkungsdauer | |
| DE3603564C2 (de) | Pharmazeutische Präparate mit analgetischer Wirksamkeit auf der Grundlage von Diclofenac | |
| EP1315481A1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
| DE69108143T2 (de) | Rotogranulate und geschmacksabdeckende Überzüge zur Herstellung pharmazeutischer Kautabletten. | |
| DE69922664T2 (de) | Acetaminophen mit verlängerter freisetzung | |
| DE69209764T2 (de) | Geschmacksabdeckende Überzüge zur Herstellung pharmazeutischer Kautabletten | |
| US4954349A (en) | Oral magnesium and potassium compositions and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8126 | Change of the secondary classification |
Ipc: A61K 9/28 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |